Vilanterol trifenatate for the treatment of COPD

Mario Malerba, Alessandro Radaeli, Paolo Montuschi, Jaymin B. Morjaria

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Currently the treatment of chronic obstructive pulmonary disease (COPD) has limited effectiveness and there is a need to develop new drugs. International guidelines recommend the use of long-acting bronchodilators (β2 agonists and anti-cholinergics/muscarinics), inhaled steroids and associations between these drugs in the maintenance treatment of moderate-to-severe COPD. Area covered: Vilanterol trifenate is a new once-daily highly selective β2-agonist available in USA and Europe in association with umeclidinium bromide (a long-acting anti-muscarnic agent) and fluticasone furoate (an inhaled corticosteroid) for the once-daily maintenance treatment of COPD. Vilanterol combined in fixed-dose treatments has been tested in numerous clinical trials involving thousands of patients. Expert commentary: These new once-daily formulations have the potential to improve compliance to long-term inhaled therapy. This paper will review the clinical and experimental data regarding vilanterol use in the regular treatment of COPD as well as provide a critical discussion of possible future treatment settings.

Original languageEnglish
Pages (from-to)719-731
Number of pages13
JournalExpert Review of Respiratory Medicine
Volume10
Issue number7
DOIs
Publication statusPublished - 2 Jul 2016
Externally publishedYes

Keywords

  • COPD treatment
  • LABA
  • LAMA
  • Vilanterol trifenate
  • fluticasone furoate
  • umeclidinium bromide

Fingerprint

Dive into the research topics of 'Vilanterol trifenatate for the treatment of COPD'. Together they form a unique fingerprint.

Cite this